Ceravis Tablet 10/40 milligrams
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Korea Pavis Pharmaceutical
MFDS item code 201906590 · Approved 2019.09.20
This product's status changed to Expired on 2024.09.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower blood pressure in patients with essential hypertension whose blood pressure is not sufficiently controlled with either amlodipine or olmesartan medoxomil as monotherapy.
This medicine is administered as 1 tablet once daily with water, regardless of food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil); however, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with decreased effective intravascular volume: For patients who may have decreased effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment (see section 2, Contraindications). ∘Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
The safety and efficacy in pediatric patients under 18 years of age have not been established.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, therefore it should be discontinued immediately upon confirmation of pregnancy. Individuals with allergies to this medication or similar drugs, pregnant or nursing women, patients with severe liver impairment, those with severe aortic stenosis, patients with biliary obstruction, those receiving renal dialysis, patients in shock, certain diabetic patients, and patients with severely impaired kidney function should not take this medication. Patients with low blood pressure due to fluid or salt depletion may experience a significant drop in blood pressure upon initial administration of this medication, so careful monitoring of their condition is necessary at the start. This medication has a vasodilatory effect, and patients with heart or vascular issues should take it with caution. Patients with impaired kidney function or severe liver impairment should regularly check their kidney and liver status while taking this medication. Side effects such as dizziness, headache, hypotension, cough, indigestion, rash, edema, etc., may occur when taking this medication, so any unusual symptoms should be discussed with healthcare professionals. It is especially advised not to take this medication during pregnancy, and if planning to become pregnant, it is recommended to switch to another safe treatment. Women who are breastfeeding are advised to discontinue breastfeeding or stop taking the medication as it may be transferred into breast milk. Children under the age of 18 are not recommended to take this medication as the safety and effectiveness have not been established. Elderly patients may have reduced kidney and liver function, so dosages should be adjusted and monitored closely while taking this medication. In cases of overdose, severe hypotension and vascular dilation may lead to cardiac issues, requiring prompt medical attention.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 degree and 30 degrees Celsius. This will ensure the medication's safety and effectiveness.
Brownish-red, round film-coated tablet
30 tablets/PTP [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Korea Pavis Pharmaceutical
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.